OncoMatch/Clinical Trials/NCT06451497
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Is NCT06451497 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ZM008 for non small cell lung cancer.
Treatment: ZM008 — This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Pembrolizumab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Esophageal Carcinoma
Head and Neck Squamous Cell Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Prostate Cancer
Urothelial Carcinoma
Colorectal Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Hemoglobin ≥9 g/dL (no transfusions in weeks); ANC ≥1.0 × 10^9/L (no growth factors in 2 previous weeks); Platelet count ≥75 × 10^9/L (no platelet transfusions in 2 previous weeks)
Kidney function
Estimated creatinine clearance (CrCL) ≥30 mL/minute (Cockcroft-Gault); if calculated CrCL <30 mL/min, measured CrCL ≥30 mL/min
Liver function
Total bilirubin ≤1.5 times ULN; AST and ALT ≤3.0 times ULN (≤5.0 times ULN if liver metastases present)
The patient has adequate hematologic function as defined by: Hemoglobin ≥9 g/dL... ANC ≥1.0 × 10^9/L... Platelet count ≥75 × 10^9/L... The patient has adequate hepatic function as defined by: Total bilirubin ≤1.5 times ULN. AST and ALT ≤3.0 times ULN, (if liver metastases are present, then ≤5.0 times ULN is allowed). The patient has adequate renal function as defined by: Estimated creatinine clearance (CrCL) using the Cockcroft-Gault formula ≥30 mL/minute. Patients with calculated CrCL <30 mL/minute can be enrolled if measured CrCL is ≥30 mL/minute.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana Farber Cancer Institute · Boston, Massachusetts
- NEXT Oncology · Austin, Texas
- NEXT Oncology · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify